NCT05475678 2025-01-23
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Henan Cancer Hospital
Phase 2 Recruiting
Clinical Trials
13 trialsNCT05355168 2024-12-31
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Anhui Provincial Hospital
Phase 2 Completed
NCT06231680 2024-03-29
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Phase 2 Unknown
NCT05189483 2024-02-07
Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.
Henan Cancer Hospital
Phase 2 Unknown
NCT05624099 2023-10-19
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Fujian Cancer Hospital
Phase 2 Recruiting
NCT04675866 2022-04-15
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
Henan Cancer Hospital
Phase NA Unknown
NCT04901754 2021-12-08
CAMERA
Henan Cancer Hospital
Phase 2 Unknown
NCT04832204 2021-04-05
Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
Beijing Hospital
Phase 2 Unknown
NCT04102982 2020-11-02
MWA in NSCLC
Shandong Provincial Hospital
Phase 2 Unknown
NCT04213898 2019-12-30
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Henan Cancer Hospital
Phase 1/2 Unknown
NCT04174339 2019-11-22
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase NA Unknown
NCT03986515 2019-06-14
Apatinib Plus SHR1210 in Advanced Mucosal Melanoma
Henan Cancer Hospital
Phase 2 Unknown
NCT03755115 2019-01-16
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown